CollabRx to Collaborate With the University of Chicago Medical Center on Clinical Cancer Sequencing and Interpretation

CollabRx to Collaborate With the University of Chicago Medical Center on
Clinical Cancer Sequencing and Interpretation

SAN FRANCISCO, June 18, 2013 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX),
a data analytics company focused on informing clinical decision making in
molecular medicine, today announced a collaboration with the thoracic oncology
program at the University of Chicago Medical Center, one of the nation's
leading cancer treatment centers with innovative clinical and translational
research programs in cancer genetics and therapeutics.

The joint initiative will combine CollabRx content and technology resources
with the results of genetic sequencing-based tests conducted at the University
of Chicago Medical Center. The tests are designed to enable physicians to
consider a tumor's unique genetic profile in cancer treatment planning. The
collaboration will be led at the University of Chicago Medical Center by Ravi
Salgia, MD, PhD, a professor of medicine and vice chair of translational
research at the University of Chicago.

"Our program is committed to identifying optimal treatments for cancer
patients using a holistic approach," said Dr. Salgia. "This commitment
includes consideration of drugs and other therapies that target genetic
abnormalities in tumors. These genetic abnormalities can now be efficiently
identified using cancer mutation panels based on next generation sequencing
technologies. CollabRx's expert systems add substantial value to these panels
by infusing interpretation and insight from recognized thought leaders who
have a deep knowledge of the latest scientific and medical research in
molecular oncology and, more importantly, understand how to apply this
knowledge to inform treatment planning at the point of care. We are highly
enthusiastic about working with CollabRx to bring its unique capabilities to
bear in optimizing patient care for those with thoracic cancers at the
University of Chicago Medical Center."

Under the terms of the collaboration, CollabRx will provide a turnkey medical
informatics solution by pairing the results of cancer mutational panels
conducted by Dr. Salgia and colleagues at the medical center with clinically
actionable and dynamically updated knowledge provided by CollabRx. Such
knowledge includes the clinical impact of specific mutational profiles and
associated therapeutic strategies such as drugs and clinical trials. It is
also supported by CollabRx's large and growing network of over 75 leading
experts and clinical practitioners in the U.S. and Europe. The medical
informatics solution will be customized, for example, by taking into account
the clinical experience of Dr. Salgia and colleagues as well as highlighting
clinical trials at the University of Chicago for which patients may be
eligible based on their tumor's genetic signature.

"We are honored to be working closely with the thoracic oncology program at
the University of Chicago Medical Center to build out a full set of
capabilities to support a precision oncology approach to cancer treatment
planning," said Thomas R. Mika, CollabRx Chairman, President and Chief
Executive Officer. "The goal of our collaboration is nothing less than to
improve cancer patient care by unlocking the full potential of next generation
sequencing of patient tumors."

Academic-based cancer treatment and research centers are among the earliest
adopters of next-generation technologies to support clinical sequencing of
tumors for the purpose of improving cancer treatment planning. The
collaboration with the thoracic oncology program at the University of Chicago
Medical Center is indicative of CollabRx's intent to provide to these top-tier
cancer treatment centers a customized interpretive service paired with
clinical genetic sequencing tests.

About CollabRx

CollabRx, Inc. (Nasdaq:CLRX) is a recognized leader in cloud-based expert
systems to inform healthcare decision-making. CollabRx uses information
technology to aggregate and contextualize the world's knowledge on
genomics-based medicine with specific insights from the nation's top cancer
experts, starting with the area of greatest need: advanced cancers in patients
who have effectively exhausted the standard of care. More information may be
obtained at http://www.collabrx.com.

About thoracic oncology at the University of Chicago

The thoracic oncology program at the University of Chicago medical center is
known for its innovative clinical trials portfolio including all phases of
clinical studies and for its extensive research on the genetic basis of
cancer, thoracic imaging, and pharmacogenomics research. More than 200
University of Chicago physicians and scientists perform groundbreaking cancer
research of all types and translate their discoveries into personalized
medicine to prevent and treat every form of cancer. Cancer care faculty and
staff also bring the latest information on prevention and treatment to
community physicians.

CollabRx Safe Harbor Statement

This press release includes forward-looking statements about CollabRx's
anticipated results that involve risks and uncertainties. Some of the
information contained in this press release, including, but not limited to,
statements as to industry trends and CollabRx's plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by such
forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual results
to differ materially from those in the forward-looking statements are detailed
in filings made by CollabRx with the Securities and Exchange Commission.
CollabRx undertakes no obligation to update or revise any such forward-looking
statements to reflect subsequent events or circumstances.

CONTACT: CollabRx Contacts:
         Gavin J. Gordon, MBA, PhD
         Vice President of Business Development & Strategic Alliances
         CollabRx, Inc.
         415-248-5350
        
         Robert Ferri Partners, LLC
         Robert Ferri
         (415) 575-1589 (direct)
         robert.ferri@robertferri.com
        
         University of Chicago Medical Center Contact:
         John Easton, (773) 795-5225
         john.easton@uchospitals.edu

CollabRx, Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.